NZX-listed AFT Pharmaceuticals has lowered its full-year earnings guidance due to deferred licensing income after delays in the US registration of Maxigesic IV, the intravenous form of its flagship pain relief medicine, and investment in growth.
New guidance for the year to March 31, 2023 is
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
